TABLE 4.

Prophylaxis of neutralizing MAbs against antibody-enhanced, lethal infection with DENV-2 D2S10a

Enhancing antibody (description)MAb prophylaxisNo. of mice that survived/total no. of micebP valuec
98J serum (25 μl; anti-DENV-1 polyclonal immune serum)PBS0/5
DV2-445/5<0.003
DV2-765/5<0.003
DV2-1045/5<0.003
4G2 (20 μg; DII-fusion loop-specific MAb)PBS0/5
DV2-445/5<0.003
DV2-765/5<0.003
DV2-1045/5<0.003
IgG2a (20 μg; nonenhancing)PBS5/5<0.003
NMS (nonenhancing)PBS5/5<0.003
  • a Six- to eight-week-old AG129 mice were administered by an intraperitoneal route either 25 μl of anti-DENV-1 98J polyclonal immune or naïve mouse serum (NMS) in 200 μl PBS, or 20 μg of the flavivirus cross-reactive fusion loop MAb 4G2 or an isotype control IgG2a MAb. Immediately after, mice were given 50 μg of the indicated anti-DENV-2 MAb. Twenty-four hours after antibody transfer, mice were infected with 105 PFU of DENV-2 D2S10 intravenously. Morbidity and mortality were measured for 10 days.

  • b The antibody-enhanced mortality measured between days 0 and 10 is due to a vascular leakage syndrome, as previously described (2, 72).

  • c The P value was calculated using the log rank analysis of a Kaplan-Meier survival curve compared to mice treated with PBS.